COMP <GO>
TWST vs IBRX // RSI-14 & 200D SMA MOMENTUM
Twist Bioscience Corporation (NASDAQ) VS. ImmunityBio Inc. (NASDAQ) • 15-METRIC TALLY: TWST 8
— IBRX 3
▲ RSI-14 & 200D SMA MOMENTUM LEADER: TWST
LAST: $152.78 (-11.92%) • MKT CAP: $10.13B
rsi-technicals
48.4
LAST: $8.29 (-5.15%) • MKT CAP: $8.79B
rsi-technicals
44.3
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TWST VS. IBRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TWST | IBRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 94.20% | 96.00% | -1.80 | IBRX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.70% | -27.30% | +15.60 | TWST | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.66% | -3.33% | +2.67 | TWST | /fcf-yield <GO> |
| Operating Margin | -4.20% | -60.00% | +55.80 | TWST | /operating-margins <GO> |
| Net Profit Margin | -2.40% | -60.00% | +57.60 | TWST | /net-margins <GO> |
| Revenue Growth (YoY) | 16.50% | 180.00% | -163.50 | IBRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 0.45 | +25.55 | TWST | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 6/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 48.4 | 44.3 | +4.10 | TWST | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 1.05 | -0.07 | IBRX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 29.0x | -8.00 | TWST | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.13B | $8.79B | $1.34B | TWST | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TWST REV | IBRX REV | TWST GROSS % | IBRX GROSS % | TWST FCF | IBRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $113.3M | — | 99.3% | -$75.6M | -$308.8M |
| FY 2024 | $0 | $14.7M | — | 100.0% | -$69.2M | -$398.1M |
| FY 2023 | $0 | $622.0K | — | — | -$142.5M | -$366.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TWST // BETA 0.98
IBRX // BETA 1.05